IP Library › Granted Patent US 12,186,428
Granted Patent B2
US 12,186,428 · App. 17/986,430 · Granted Jan 7, 2025

Combination taxoid nanoemulsion with immunotherapy in cancer

Inventors: James E. Egan (Stony Brook, NY); Mansoor M. Amiji (Attleboro, MA); Iwao Ojima (Port Jefferson, NY)
Assignees: TargaGenix, Inc.; The Research Foundation for the State University of New York; Northeastern University
A61K9/1075A61K31/337A61K39/39558A61K47/44A61K47/542A61P35/00C07K16/2827A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,428
App. No.
17/986,430
Granted
Jan 7, 2025
Kind
B2
Abstract

A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.

Claims (18)

1. A pharmaceutical composition comprising an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology ( 10 ) agent of anti-PD-L1 antibody, wherein said PUFA-taxoid conjugate is NE-DHA-SBT-1214.

2. The pharmaceutical composition of claim 1 , wherein said PUFA is chosen from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and alpha-linolenic acid (LNA).

3. The pharmaceutical composition of claim 1 , wherein said oil-in-water NE includes omega-3 fatty acid-rich edible oil.

4. The pharmaceutical composition of claim 3 , wherein said omega-3 fatty acid-rich edible oil is chosen from the group consisting of fish oil, flax-seed oil, pine nut oil, safflower oil, primrose oil, black currant oil, borage oil, wheat germ oil, chia oil, hemp oil, perilla oil, grape oil, squalene oil, and fungal oil.

5. The pharmaceutical composition of claim 3 , wherein said omega-3 fatty acid-rich edible oil is modified with a compound chosen from the group consisting of surfactants and targeting agents.

6. A method of treating cancer, including the steps of:

administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an NE drug delivery system, wherein said PUFA-taxoid conjugate is NE-DHA-SBT-1214, in combination with an IO agent of to a subject in need of treatment; and

treating pancreatic cancer.

7. The method of claim 6 , further including the steps of increasing expression of PD-L1 in the tumor microenvironment, increasing CD4 + and CD8 + tumor-infiltrating lymphocytes, and making the subject more responsive to the IO agent.

8. The method of claim 6 , wherein the cancer is highly drug resistant.

9. The method of claim 6 , further including the step of down-regulating survival genes in tumors and activating p53 and p21.

10. The method of claim 6 , wherein the PUFA is chosen from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and alpha-linolenic acid (LNA).

11. The method of claim 6 , further including the step of upregulating PD-L1.

12. The method of claim 6 , wherein the oil-in-water NE includes omega-3 fatty acid-rich edible oil.

13. The method of claim 12 , wherein the omega-3 fatty acid-rich edible oil is chosen from the group consisting of fish oil, flax-seed oil, pine nut oil, safflower oil, primrose oil, blackcurrant oil, borage oil, wheat germ oil, chia oil, hemp oil, perilla oil, grape oil, squalene oil, and fungal oil.

14. The method of claim 12 , wherein the omega-3 fatty acid-rich edible oil is modified with a compound chosen from the group consisting of surfactants and targeting agents.

15. The method of claim 6 , wherein a tumor treated has less dense stroma after treatment.

16. The method of claim 6 , further including the steps of increasing intra-tumoral IFN-gamma producing T cells and inducing infiltration of inflammatory macrophages.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2022
From: EGAN, JAMES E.; AMIJI, MANSOOR; OJIMA, IWAO
To: TARGAGENIX, INC.; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK; NORTHEASTERN UNIVERSITY
Reel/Frame 061807/0710 →
Continuity (3)
Division 16225629 · Dec 19, 2018
Provisional Application 62608015 · Dec 20, 2017
Related Publication 20230082272A1 · Mar 16, 2023
References Cited (55)
US 7820839B2 · Ojima · 2010 [cited by examiner]
US 10206875B2 · Egan · 2019 [cited by examiner]
US 11497713B2 · Egan · 2022 [cited by examiner]
US 20070148194A1 · Amiji · 2007 [cited by examiner]
Ahmad, et al., Cancer Letters 2017, 406:71 (Year: 2017). [cited by examiner]
BMS, Clinical Trial No. NCT00730639, Aug. 7, 2008; Available online: https://www.clinicaltrials.gov/study/NCT00730639?cond=NCT00730639&rank=1&tab=history&a=1 (Year: 2008). [cited by examiner]
Bellet, et al., Journal of Clinical Oncology 2004, 22:1457 (Year: 2004). [cited by examiner]
Celgene, Clinical Trial No. NCT02309177, Dec. 4, 2014; Available online: https://www.clinicaltrials.gov/study/NCT02309177?cond=NCT02309177&rank=1&tab=history&a=1 (Year: 2014). [cited by examiner]
Theradex, US clinical trial: NCT00024375; Jun. 23, 2005; URL: https://www.clinicaltrials.gov/study/NCT00024375?cond=NCT00024375&rank=1&tab=history&a=1 (Year: 2005). [cited by examiner]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65: 5-29. [cited by applicant]
Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012;13: 1308-23. [cited by applicant]
Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. Journal … [cited by applicant]
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med… [cited by applicant]
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouam Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer… [cited by applicant]
Hutchinson L, Kirk R. High drug attrition rates—where are we going wrong? Nature reviews Clinical oncology 2011;8: 189-90. [cited by applicant]
Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 200… [cited by applicant]
Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem 2008;51: 3203-21. [cited by applicant]
Botchkina GI, Zuniga ES, Das M, Wang Y, Wang H, Zhu S, Savitt AG, Rowehl RA, Leyfman Y, Ju J, Shroyer K, Ojima I. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced… [cited by applicant]
Das M, Zuniga E, Ojima I. Novel Taxoid-Based Tumor-Targeting Drug Conjugates. Chim Oggi 2009;27: 54-6. [cited by applicant]
Sauer LA, Dauchy RT. The effect of omega-6 and omega-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. British journal of cancer 1992;66: 297-303. [cited by applicant]
Harries M, O'Donnell A, Scurr M, Reade S, Cole C, Judson I, Greystoke A, Twelves C, Kaye S. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. British j… [cited by applicant]
Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006;17: 735-49. [cited by applicant]
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342: 1432-3. [cited by applicant]
Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 2015;11: 1307-26. [cited by applicant]
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Ca… [cited by applicant]
Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373: 1270-1. [cited by applicant]
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized… [cited by applicant]
Li X, Hu W, Zheng X, Zhang C, Du P, Zheng Z, Yang Y, Wu J, Ji M, Jiang J, Wu C. Emerging immune checkpoints for cancer therapy. Acta Oncol 2015;54: 1706-13. [cited by applicant]
Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L. Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. J Cancer 2018;9: 205-12. [cited by applicant]
Xu-Monette ZY, Zhang M, Li J, Young Kh. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol 2017;8: 1597. [cited by applicant]
Torphy RJ, Schulick RD, Zhu Y. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. Int J Moll Sci 2017;18. [cited by applicant]
They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissiere-Michot F, Jarlier M, Mollevi C, Ellaou JF, Bonnefoy N, Gros L. PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects o… [cited by applicant]
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway i… [cited by applicant]
Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, Yagita H, Miura S. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. I… [cited by applicant]
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory s… [cited by applicant]
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topallan SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 201… [cited by applicant]
Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Jr., Donehower RC, Jaffee EM, Laheru DA. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gen… [cited by applicant]
Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Warnwea A, Yager A, Laheru D, Wolfgang CL, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation… [cited by applicant]
Ghebeh H, Lehe C, Barhoush E, Al-Romalh K, Tulbah A, Al-Alwan M, Hendrayani SF, Manogaran P, Alaiya A, Al-Tweigeri T, Aboussekhra A, Dermime S. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its… [cited by applicant]
Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, Konishi I, Mandal M. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factorkapp… [cited by applicant]
Ganta S, Singh A, Rawal Y, Cacaccio J, Patel NR, Kulkarni P, Ferris CF, Amiji MM, Coleman TP. Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian… [cited by applicant]
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 20… [cited by applicant]
Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77: 1561-5. [cited by applicant]
Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90: 9552-6. [cited by applicant]
Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,… [cited by applicant]
Sakal H, Kokura S, Ishikawa T, Tsuchiya R, Okajima M, Matsuyama T, Adachi S, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, et al. Effects of anticancer agents on cell viability, proliferative activity and cytokine … [cited by applicant]
Okino H, Maeyama R, Manabe T, Matsuda T, Tanaka M. Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice. Clinical cancer resea… [cited by applicant]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer 2012;12: 252-64. [cited by applicant]
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member lead… [cited by applicant]
Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22: 265-8. [cited by applicant]
Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl A… [cited by applicant]
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005;17: 133-44. [cited by applicant]
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer research … [cited by applicant]
Lukens JR, Cruise MW, Lassen MG, Hahn YS. Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol 2008;180: 4875-84. [cited by applicant]
Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer research 2005;65: 3437-46. [cited by applicant]